J.P. Morgan analyst Anupam Rama has maintained their bullish stance on TVTX stock, giving a Buy rating on November 7.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Anupam Rama’s rating is based on several compelling factors surrounding Travere Therapeutics. The potential approval of Filspari for the treatment of FSGS is a significant driver, as key opinion leaders at a recent conference indicated that the drug would see widespread and rapid adoption upon approval. This sentiment is supported by data from the DUPLEX study, which demonstrated that Filspari significantly reduced proteinuria compared to irbesartan, suggesting a strong therapeutic benefit.
Additionally, the positive reception of Filspari in treating IgAN, where it is preferred over Vanrafia due to full approval and real-world experience, further supports the Buy rating. The modifications in the REMS for Filspari have not hindered its utilization, indicating that the drug’s market potential remains robust. These factors, combined with the strategic attractiveness of Travere as a company, underpin Anupam Rama’s optimistic outlook on the stock.
In another report released on November 7, H.C. Wainwright also reiterated a Buy rating on the stock with a $47.00 price target.
TVTX’s price has also changed dramatically for the past six months – from $20.230 to $32.340, which is a 59.86% increase.